Cdk2 inhibitors and methods of using same

A compound of Formula (I),

• wherein
• X is CH or N;
• Z is CH or N;
• ring A is aryl, heteroaryl, cycloalkyl or heterocyclyl, or aryl-fused heterocyclyl, each of which is optionally and independently substituted with one R1 and one to four R2;
• wherein a carbon atom of the aryl-fused heterocyclyl is optionally substituted with one oxo, and a heteroatom of the aryl-fused heterocyclyl is optionally substituted with one or two oxo;
• R1 is —S(O)2—R10, —NH—S(O)2—R10 or —SF5;
• each R2 is independently H, alkyl, —CN, cyanoalkyl, amino, alkylamino, dialkylamino, —NO2, halo, haloalkyl, hydroxyl, hydroxyalkyl, alkoxyl, haloalkoxy, (haloalkoxy)alkyl, alkoxyalkyl, cycloalkyl or heterocyclyl;
• wherein the cycloalkyl or heterocyclyl is optionally substituted with one or more R7;
• R3 is H, halo, alkyl, haloalkyl, hydroxyl, hydroxyalkyl, alkoxyl, alkoxyalkyl, alkenyl, alkynyl, —CN or cyanoalkyl;
• R4 and R6 are each independently H, alkyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, alkoxyl, haloalkoxy, (haloalkoxy)alkyl, alkoxyalkyl, amino, alkylamino, dialkylamino, -alk-N—R9R9, —CN, cyanoalkyl, cycloalkyl or heterocyclyl;
• wherein the cycloalkyl or heterocyclyl is optionally substituted with one or more R7;
• R5 is H, alkyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, alkoxyl, haloalkoxy, (haloalkoxy)alkyl, alkoxyalkyl, —CN, cyanoalkyl, amino, alkylamino, dialkylamino, -alk-N—R9R9, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, -alk-cycloalkyl, -alk-heterocyclyl, —O-cycloalkyl, or —O— heterocyclyl, wherein the aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocyclyl, -alk-cycloalkyl, -alk-heterocyclyl, —O-cycloalkyl or —O-heterocyclyl is optionally substituted with one or more R7;
• each R7 is independently alkyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, alkoxyl, haloalkoxy, (haloalkoxy)alkyl, alkoxyalkyl, amino, alkylamino, dialkylamino, —CN, cyanoalkyl, oxo (═O), R8—S(O)2—, R8—O—C(═O)—, R8—C(═O)—O—, R8—C(═O)—, cycloalkyl or heterocyclyl;
• wherein the cycloalkyl or heterocyclyl is optionally further substituted with one or more R7;
• each R8 is independently H, alkyl or —NR9R9;
• each R9 is independently H, cycloalkyl, -alk-cycloalkyl, or alkyl;
• R10 is H, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, heterocyclyl or —NR11R11;
• wherein the cycloalkyl or heterocyclyl is optionally substituted with one or more R7;
• each R11 is independently H, alkyl, cycloalkyl, heterocyclyl, -alk-cycloalkyl, -alk-heterocyclyl, hydroxyalkyl, -alk-O—R12, -alk-C(O)—OR9 or -alk-N—R9R9;
• wherein the cycloalkyl, -alk-cycloalkyl, -alk-heterocyclyl, or heterocyclyl is optionally substituted with one or more R7;
• each R12 is independently H, alkyl, cycloalkyl, haloalkyl, or heterocyclyl;
• the heteroaryl and heterocyclyl in each occurrence independently contain one or more ring-forming heteroatoms each of which is independently oxygen, sulfur or nitrogen;
• the heterocyclyl in each occurrence is saturated or partially unsaturated;
• and
• any H in each alkyl is optionally replaced with deuterium (D);
• or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.